Andrew L. Wilson, PharmD, FASHP, Vice President, McKesson 340B Solutions

home / authors / andrew-l-wilson-pharmd-fashp-vice-president-mckesson-340b-solutions

Articles

Understanding and Navigating Specialty and Orphan Drug Challenges in the 340B Program

Lisa Nezneski, PharmD, BCPS, Managing Consultant, McKesson 340B Solutions;Christopher S. Shain, PharmD, BCPS, Assistant Vice President, McKesson 340B Solutions;Andrew L. Wilson, PharmD, FASHP, Vice President, McKesson 340B Solutions

March 15th 2019

Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.

Published: October 23rd 2024 | Updated: October 24th 2024

What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders